---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004053"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2026-06-11T13:20:32+00:00"
generated_at: "2026-06-11T13:21:20.056014+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech announces $3.5M PIPE led by CEO; funds vitiligo program

## Summary
- Gross proceeds ~$3.5M from sale of 729,241 common shares to healthcare-focused investors and CEO.
- Investors pay $4.69/share; CEO pays $5.21/share; closing expected June 15, 2026.
- Net proceeds to fund advancement of vitiligo program and drug candidate paridiprubart, plus working capital.
- Company entered Registration Rights Agreement to file resale registration statement within 45 days of closing.
- Securities offered under Section 4(a)(2) and Regulation D; no underwriter or placement agent used.

## SEC filing metadata
- accession: 0001171843-26-004053
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2026-06-11T13:20:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/0001171843-26-004053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/f8k_061026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004053
- JSON: https://secwatch.observer/filing/0001171843-26-004053.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004053.txt

## Key facts
- Equity Issuances
  Edesa Biotech, Inc. issued an aggregate of 729,241 common shares of common stock to certain investors for aggregate purchase price of approximately $3.5 million.
  - Security: common stock
  - Shares: an aggregate of 729,241 common shares
  - Purchaser: certain investors
  - Consideration: aggregate purchase price of approximately $3.5 million
  source text: Pursuant to the Purchase Agreement, the Purchasers have agreed to purchase, for an aggregate purchase price of approximately $3.5 million, an aggregate of 729,241 common shares (“Shares”), without par value, at a purchase price of $4.69 per Share for Purchasers other than the Company’s Chief Executive Officer, and $5.21 per Share for the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/0001171843-26-004053-index.htm
- Material Agreements
  Edesa Biotech, Inc. entered into Securities Purchase Agreement with certain investors (each, a Purchaser and collectively, the Purchasers) valued at $3.5 million aggregate purchase price for 729,241 common shares at $4.69 per Share ($5.21 per Share (effective 2026-06-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors (each, a Purchaser and collectively, the Purchasers)
  - Value: $3.5 million aggregate purchase price for 729,241 common shares at $4.69 per Share ($5.21 per Share
  - Effective: 2026-06-10
  source text: On June 10, 2026, Edesa Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain investors (each, a “Purchaser” and collectively, the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/0001171843-26-004053-index.htm
- Material Agreements
  Edesa Biotech, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company agrees to file registration statement for resale of shares within 45 days after Closing (effective 2026-06-10).
  - Action: entry
  - Counterparty: the Purchasers
  - Value: Company agrees to file registration statement for resale of shares within 45 days after Closing
  - Effective: 2026-06-10
  source text: Also on June 10, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/0001171843-26-004053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.